Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

ARNA 4.12 -0.02 (-0.48%)
price chart
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surging on Rumors?  HotStocked
3 Reasons to Buy VIVUS  DailyFinance
Related articles »  
Earnings Preview: Arena Pharmaceuticals
Arena Pharmaceuticals (NASDAQ:ARNA) is scheduled to report its Q2 2012 results on Aug. 9, 2012, after the bell. The Street expects an EPS loss of $0.08 and revenue of $7.38 million.
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation  Insider Monkey (blog)
Will pill-popping beat obesity?
Related articles »  
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Related articles »  
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
Related articles »  
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Related articles »  
5 Bio-Pharma Stocks To Buy Right Here
The company is making money now or close to it, has diverse products (hormone delivery, arthritis, contraception...), and long term nestragel and male contraceptives could be really huge (women preferred their contraceptive gel to a pill 3-1).
Related articles »  
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Related articles »  
How Much Can Vivus, Arena Pharma Charge for Diet Pills?
Lief told investors on a conference call that his company's partnership with Eisai is one of the reasons he feels confident about his drug's chances for success.
Related articles »  
Theravance: Buy This Biopharma On Weakness
Arena Pharmaceuticals (NASDAQ:ARNA) came up while researching Theravance (NASDAQ:THRX) and Valeant Pharmaceuticals (NYSE:VRX). Since July 16, Arena dropped from $11.11 to $7.27, ... Both VVUS and Arena should be expected to report losses as the ...